Here’s what physicians need to know about sudden cardiac death
M3 Global Newsdesk Jul 31, 2022
Sudden cardiac death (SCD), an unexpected death caused by the abrupt loss of heart function, breathing, and consciousness is a daunting prospect for physicians, medical teams, and EMS responders. And with good reason, it is a leading cause of mortality and results in half of all deaths due to heart disease. This article speaks about the factors that cause it and its management.
Most researchers define sudden cardiac death as sudden death from a cardiovascular cause that occurs within 1 hour of witnessed symptom onset. When unwitnessed, it refers to death within the previous 24 hours that the person was last seen alive. Importantly, pulmonary embolism, stroke, and aortic syndromes are all differential diagnoses for this dreaded disease.
SCD is caused by a sudden malfunction of the heart’s electrical system, which is different from myocardial infarction, which is caused by a blockage of blood flow to the heart but SCD can occur during a heart attack.
According to the authors of a review article published in Heart, Lung and Circulation:
“Despite its importance and societal burden, our understanding of SCD epidemiology is limited. The epidemiological study of SCD has been particularly hampered by definitional and methodological challenges. Although much progress has been made through implantable cardioverter defibrillators, community-based cardiopulmonary resuscitation, and coronary heart disease (CHD) management, SCD still remains the cause of 15-20% of deaths in western societies.”
Furthermore, according to research presented at the Heart Rhythm 2021 hybrid event this past summer, SCA incidence has been significantly higher and survival outcomes lower during the COVID-19 pandemic period, with evidence of overlap between the two conditions. To better understand this major public health burden, here’s a closer look at SCA risk factors, treatment, and prevention.
Who is at risk?
Age- The risk of SCD increases with age. Notably, of people 35 years or younger, the greatest risk is in those aged between 0 and 5 years.
Sex- Recent studies indicate that men are three or four times more likely to experience SCD than are women. Nevertheless, this gap may be eroding.
Coronary heart disease
Although rates differ by age, gender, race, and ethnicity, coronary heart disease is hypothesised to be the structural foundation for nearly 70% of SCD events overall. Surprisingly, CHD is estimated to be the second leading cause of death in people aged between 5 and 34 years, with 22% of decedents affected. Transient ischemia, acute coronary syndromes, scar-related pathology, and ischaemic cardiomyopathy can all play a role in underlying CHD leading to SCD.
During the first month after a heart attack, the risk for myocardial infarction is greatest. Although risk decreases subsequently, ventricular remodelling and heart failure can further increase risk. In two-thirds of patients, CHD-related SCD is the first manifestation of CHD or presents in those thought to be low risk, thus making prevention more challenging.
Diseases related to CHD including hypertension, diabetes, dyslipidemia, and obesity predict SCD in men and women. Of note, 58% of decedents aged between 5 and 34 years exhibit at least one cardiovascular risk factor, according to research cited by the authors of the aforementioned review, with 39% of them also having obesity. On a related note, family history may also contribute to SCD.
Other conditions that serve as SCD risk factors include atrial fibrillation, chronic kidney disease, and obstructive sleep apnoea, as well as mental disorders including depression, anxiety, and psychosis. Cigarette smoking is also a risk factor that is predictive for SCD in men and women.
Emotional stress, heavy alcohol use, air pollution, and diurnal/seasonal variations can all trigger SCD. On the other hand, moderate consumption of alcohol and exercise may be protective. The Mediterranean diet and foods rich in fish (ie, n-3 polyunsaturated fatty acids) and magnesium may also protect.
ECG measures may present intermediate phenotypes associated with clinical risk factors and mirror the presence of structural heart disease or arrhythmia. These parameters include greater resting heart rate and markers of abnormal cardiac depolarisation and repolarisation, as well as abnormalities of primary arrhythmic disorders (eg, long and short QT syndromes, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, and Wolff-Parkinson-White syndrome). Combinations of ECG parameters may also be able to predict risk.
In the aggregate, arrhythmic disorders are hypothesised to be responsible for 1% to 2% of all SCD in Western countries. Nevertheless, there may be some ethnic/geographic variation in such genetic disorders.
According to the authors:
“In those with unexplained arrhythmic cardiac arrest not attributable to CHD or other diseases, systematic testing reveals a potential cause in approximately 50%, of which two-thirds are primary arrhythmic disorders and the remaining have the unrecognised structural disease. Arrhythmic disorders include long and short QT syndromes, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and early repolarisation syndrome.”
Non-ischaemic structural heart disease
In 15% of SCD cases, structural heart disease apart from CHD plays a role, including dilated cardiomyopathies, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, infiltrative diseases (eg, sarcoidosis, amyloidosis), valvular heart disease, and congenital abnormalities. The prevalence of this aetiology is especially pronounced among younger decedents.
How to treat
With SCD, there is little time to spare. Treatment must immediately commence at the scene including by lay people and EMS. Management includes the use of an automated external defibrillator, as well as cardiopulmonary resuscitation (CPR). CPR feeds oxygen to the brain until the establishment of a stable electrical rhythm.
According to StatPearls,
“After transfer to a hospital, therapeutic hypothermia can be induced to limit neurologic injury and reperfusion injuries. Therapeutic hypothermia is more effective for the management of ventricular tachycardia and ventricular fibrillation but can also be used in PEA and asystole. Limitations to therapeutic hypothermia include a tympanic membrane temperature below 30 degrees at presentation, being comatose before the sudden cardiac arrest, pregnancy, inherited coagulation disorder, and the terminally ill patient.”
For those who survive, treatment is aimed at the underlying pathology, including the prescription of appropriate medications. An implantable cardioverter-defibrillator (ICD) is used in case of arrhythmia-related syncope or survival.
How to prevent
Considering the dire nature of SCD, evidence-based prevention should be a focus of care especially in those at risk. Physicians can point patients to resources such as the American Heart Association, which recommends the following interventions:
- Screening for family history
- Smoking cessation
- Advising family and friends of those hospitalised with heart conditions to learn about CPR and the use of an automated external defibrillator
- Education about and use of ICDs in those with heart failure and reduced ejection fraction
SCD is an ominous event that can affect patients at any age. Because its presentation is sudden and often fatal, providers should be well-versed in its causes and treatments. Fortunately, some patient risk factors are modifiable, and physicians and EMS providers can take steps to mitigate the odds of death.
This article was originally published on 30 October 2021.
This story is contributed by Naveed Saleh and is a part of our Global Content Initiative, where we feature selected stories from our Global network which we believe would be most useful and informative to our doctor members.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries